Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.
Bibliographical noteFunding Information:
All authors received honoraria and travel support from Medtronic to present at “The SNS Summit” held in Barcelona in June 2018. Dr. Esler has been supported in part by the Victorian Government's Operational Infrastructure Support Program; has received salary support from an Australian Government NHMRC Senior Principal Research Fellowship; and has been a member of the Advisory Boards of SyMap and Medtronic. Dr. Banek is supported by National Institutes of Health grant K99 HL141650. Drs. Böhm and Mahfoud are supported by Deutsche Gesellschaft für Kardiologie, Deutsche Hochdruckliga, and Deutsche Forschungsgemeinschaft (SFB TRR 219); and have received grant support and personal fees from Medtronic and Recor Medical. Dr. Böhm has received research support and speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, and Novartis. Dr. Denton is supported by an NHMRC research fellowship; and has received travel support from Medtronic. Dr. Everett is supported in part by National Institutes of Health grant R42DA043391 and a Charles Fisch Cardiovascular Research Award endowed by Dr. Suzanne B. Knoebel of the Krannert Institute of Cardiology. Dr. Mahfoud has received research grants from and served on the Speakers Bureau of Medtronic and Recor. Dr. Paton was supported by the British Heart Foundation and the Health Research Council of New Zealand. Dr. Schmieder has received speaker fees, consultancy, and advisory board fees from Ablative Solutions, Medtronic, Recor, and ROX Medical. Dr. Pellegrino has received honoraria and travel support from Medtronic. Dr. Schlaich is supported by an NHMRC Research Fellowship; and has received consulting fees and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- blood pressure
- cardiovascular disease
- renal denervation
- sympathetic nervous system
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural